Search

Displaying results 1681 - 1690 of 8195 in total
  1. Drug

    Brilliant green cation

    go.drugbank.com/drugs/DB11279
    ApprovedVet approved

    Due to its inhibitory actions against Gram positive microorganisms, brilliant green can be found in antiseptic products such as solutions and swabs used to prevent infection.

  2. Drug

    anti-OX40 antibody BMS 986178

    go.drugbank.com/drugs/DB15773
    Investigational

    A macrocyclic peptide (BMS-986189) with activity in binding and functional assays comparable to a PD-L1 antibody.

  3. Drug

    Guanoxan

    go.drugbank.com/drugs/DB13211
    Approved

    Guanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity. … Guanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage.

  4. Drug

    Peginesatide

    go.drugbank.com/drugs/DB08894
    ApprovedWithdrawn

    Peginesatide is a synthetic peptide attached to polyethylene glycol for the treatment of anemia. The polyethylene glycol moiety helps make the drug less immunogenic and prolongs its plasma half-life. Chemically, peginesatide is designed ...

  5. Drug

    Regorafenib

    go.drugbank.com/drugs/DB08896
    ApprovedInvestigational

    Regorafenib is an orally-administered inhibitor of multiple kinases.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  6. Drug

    PF-03654764

    go.drugbank.com/drugs/DB12360
    Investigational

    PF-03654764 has been used in trials studying the basic science and treatment of Allergic Rhinitis.

  7. Drug

    Bulevirtide

    go.drugbank.com/drugs/DB15248
    ApprovedInvestigational

    Hepatitis D is considered the most severe type of viral hepatitis and leads to the rapid development of cirrhosis, severe decompensation of liver function, and an increased risk of mortality. … [L30260,L30275] Due to potentially beneficial synergistic effects in treating chronic Hepatitis D, bulevirtide is also under investigation in clinical trial NCT03852433 (Phase 2b Study of Bulevirtide With

  8. Drug

    Tabelecleucel

    go.drugbank.com/drugs/DB17072
    ApprovedInvestigational

    Tabelecleucel is an innovative therapy that uses Epstein-Barr virus (EBV)-specific allogeneic cytotoxic T cells (CTLs).

  9. Drug

    Rifamycin

    go.drugbank.com/drugs/DB11753
    ApprovedInvestigationalWithdrawn

    [L4800] This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.[L4801]

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  10. Drug

    Pesampator

    go.drugbank.com/drugs/DB11843
    Investigational

    PF-04958242 has been used in trials studying the basic science and treatment of Schizophrenia and Hearing Loss, Sensorineural.